These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37028510)

  • 21. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
    Riedl MA; Maurer M; Bernstein JA; Banerji A; Longhurst HJ; Li HH; Lu P; Hao J; Juethner S; Lumry WR;
    Allergy; 2020 Nov; 75(11):2879-2887. PubMed ID: 32452549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France.
    Fain O; Du-Thanh A; Gobert D; Launay D; Inhaber N; Boudjemia K; Aubineau M; Sobel A; Boccon-Gibod I; Weiss L; Bouillet L
    Allergy Asthma Clin Immunol; 2022 Apr; 18(1):30. PubMed ID: 35365234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema.
    Vanya M; Watt M; Shahraz S; Kosmas CE; Rhoten S; Costa-Cabral S; Mendivil J; Devercelli G; Weller K
    J Patient Rep Outcomes; 2023 Apr; 7(1):33. PubMed ID: 37012445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab.
    Shah CH; Princic N; Evans KA; Schultz BG
    J Med Econ; 2023; 26(1):871-877. PubMed ID: 37395381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey.
    Mendivil J; Murphy R; de la Cruz M; Janssen E; Boysen HB; Jain G; Aygören-Pürsün E; Hirji I; Devercelli G
    Orphanet J Rare Dis; 2021 Feb; 16(1):94. PubMed ID: 33602292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses.
    Mendivil J; Malmenäs M; Haeussler K; Hunger M; Jain G; Devercelli G
    Drugs R D; 2021 Mar; 21(1):113-121. PubMed ID: 33646565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy.
    Bova M; Valerieva A; Wu MA; Senter R; Perego F
    Drug Des Devel Ther; 2019; 13():3635-3646. PubMed ID: 31695331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema.
    Petersen RS; Bordone L; Riedl MA; Tachdjian R; Craig TJ; Lumry WR; Manning ME; Bernstein JA; Raasch J; Zuraw BL; Deng Y; Newman KB; Alexander VJ; Lui C; Schneider E; Cohn DM
    Allergy; 2024 Mar; 79(3):724-734. PubMed ID: 38009241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
    Watt M; Malmenäs M; Romanus D; Haeussler K
    J Comp Eff Res; 2023 Jun; 12(6):e220188. PubMed ID: 37218553
    [No Abstract]   [Full Text] [Related]  

  • 30. Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience.
    Hahn J; Trainotti S; Wigand MC; Schuler PJ; Hoffmann TK; Greve J
    J Drugs Dermatol; 2020 Oct; 19(10):978-983. PubMed ID: 33026762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic Treatment in Hereditary Angioedema Is Associated with Reduced Anxiety in Patients in Leipzig, Germany.
    Zarnowski J; Rabe M; Kage P; Simon JC; Treudler R
    Int Arch Allergy Immunol; 2021; 182(9):819-826. PubMed ID: 33887730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lanadelumab for the treatment of hereditary angioedema.
    Wu MA
    Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
    [No Abstract]   [Full Text] [Related]  

  • 33. Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden.
    Nordenfelt P; Nilsson M; Lindfors A; Wahlgren CF; Björkander J
    Allergy Asthma Proc; 2017 Nov; 38(6):447-455. PubMed ID: 28855002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
    Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
    N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lanadelumab: First Global Approval.
    Syed YY
    Drugs; 2018 Oct; 78(15):1633-1637. PubMed ID: 30267321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema.
    Wang Y; Marier JF; Kassir N; Chang C; Martin P
    Clin Transl Sci; 2020 Nov; 13(6):1208-1216. PubMed ID: 32407574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema.
    Castaldo AJ; Jervelund C; Corcoran D; Boysen HB; Christiansen SC; Zuraw BL
    Allergy Asthma Proc; 2021 Mar; 42(2):108-117. PubMed ID: 33581742
    [No Abstract]   [Full Text] [Related]  

  • 38. Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR.
    Yarlas A; Lovley A; McCausland K; Brown D; Vera-Llonch M; Conceição I; Karam C; Khella S; Obici L; Waddington-Cruz M
    Neurol Ther; 2021 Dec; 10(2):865-886. PubMed ID: 34355354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
    Hwang G; Johri A; Ng S; Craig T
    Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management.
    West JB; Poarch K; Lumry WR
    Clin Ther; 2021 Dec; 43(12):2154-2166.e1. PubMed ID: 34879971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.